U.S. Markets open in 37 mins.

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
135.31-1.26 (-0.92%)
At close: 4:00PM EDT

135.29 -0.02 (-0.01%)
Pre-Market: 8:00AM EDT

People also watch
Full screen
Previous Close136.57
Bid135.29 x 700
Ask135.95 x 100
Day's Range135.10 - 136.27
52 Week Range109.32 - 137.08
Avg. Volume5,618,498
Market Cap364.5B
PE Ratio (TTM)22.74
Earnings DateN/A
Dividend & Yield3.36 (2.48%)
Ex-Dividend Date2017-05-25
1y Target EstN/A
Trade prices are not sourced from all markets
  • Better Buy: Johnson & Johnson vs. AbbVie
    Motley Fool31 minutes ago

    Better Buy: Johnson & Johnson vs. AbbVie

    Which big pharma stock wins in a head-to-head battle between Johnson & Johnson and AbbVie?

  • The Wall Street Journal31 minutes ago

    [$$] Samsung Releases Lower-Cost Alternative to J&J's Drug Remicade

    South Korea’s Samsung conglomerate, best known for its smartphones and televisions, will make available on Monday in the U.S. its lower-price copy of Johnson & Johnson’s blockbuster rheumatoid-arthritis ...

  • Reuters53 minutes ago

    Samsung Bioepis launches U.S. sales of Remicade biosmiliar

    South Korea's Samsung Bioepis Co Ltd said it started U.S sales of its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade on Monday - a move set to further undermine sales of the U.S. firm's top-selling drug. It is the second cheaper biosimilar version of Remicade to be sold after Pfizer Inc's Inflectra. Remicade had U.S. sales of $4.8 billion last year, but January-June sales fell 8.2 percent from a year earlier to $2.2 billion on its new competition.